AI 检索
AI 阅读
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.

Vera A Bittner,Michael Szarek,Philip E Aylward,Deepak L Bhatt,Rafael Diaz,Jay M Edelberg,Zlatko Fras,Shaun G Goodman,Sigrun Halvorsen,Corinne Hanotin,Robert A Harrington,J Wouter Jukema,Virginie Loizeau,Patrick M Moriarty, Angèle Moryusef,Robert Pordy,Matthew T Roe,Peter Sinnaeve,Sotirios Tsimikas,Robert Vogel,Harvey D White,Doron Zahger,Andreas M Zeiher,Ph Gabriel Steg,Gregory G Schwartz

Journal of the American College of Cardiology（2020）

引用 265|浏览169
暂无评分
摘要
Baseline lipoprotein(a) and corrected LDL-C levels and their reductions by alirocumab predicted the risk of MACE after recent ACS. Lipoprotein(a) lowering by alirocumab is an independent contributor to MACE reduction, which suggests that lipoprotein(a) should be an independent treatment target after ACS. (ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; NCT01663402).
更多
查看译文
关键词
acute coronary syndromes,alirocumab,low-density lipoprotein cholesterol,major adverse cardiovascular events,proprotein convertase subtilisin/kexin type 9 inhibition
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要